ADMA Biologics Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
ADMA Biologics Inc Announces Offering Of Common Stock-Form S-1/A
ADMA Biologics Inc announced in its Form S-1/A that it is offering 2,100,000 shares of common stock. The Company estimate that the offering price will be between $13.50 and $15.50 per share. 7,971,002 shares (or 8,286,002 shares if the underwriters exercise their overallotment option in full). The underwriters have a 30-day option to purchase up to an additional 315,000 shares of common stock at the public offering price less the underwriting discount and commission. The Company estimate that the net proceeds from this offering, after deducting the underwriting discount and commission and estimated offering expenses payable by the Company, will be approximately $27.3 million. The Company intend to use the proceeds of this offering to continue clinical development and testing of RI-002 and for working capital and other general corporate purposes.
Latest Developments for ADMA Biologics Inc
- Share this
- Digg this